POLBFPoolbeg Pharma Plc

About Poolbeg Pharma Plc (POLBF)

Poolbeg Pharma Plc (POLBF) is a Biotechnology company headquartered in London, ENG, United Kingdom whose shares trade over-the-counter on the Pink tier.

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Products and services

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity. POLB 001 has the potential to be an effective treatment for severe influenza, as well as a breakthrough orally delivered preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). CRS is a severe inflammatory response, which may be encountered as a side effect of some therapies, manifesting a range of symptoms that can rapidly progress to a severe life-threatening reaction. An effective therapy for CRS could unlock the benefits of cancer immunotherapies; benefiting patients, healthcare systems and pharma companies alike. The market potential for POLB 001 exceeds US$10 billion in the cancer setting alone, according to independent research. The Company is progressing towards a proof-of-technology clinical trial for an oral GLP-1R agonist for obesity with the aim of tapping into the fast-growing GLP-1 agonist market which is expected to reach $150bn by 2031. Poolbeg has identified novel drug target and treatments for RSV and influenza by analysing unique human challenge trial data using artificial intelligence. AI-led solutions typically enable faster target identification, at lower cost, reduced risk, and potentially increased likelihood of success. The Company continues to actively discuss the exciting outputs from these AI-led drug discovery programmes with prospective partners.

POLBF key facts

Ticker symbol

POLBF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

London, ENG, United Kingdom

Country of incorporation

GB

Year of incorporation

2021

Employees

14

Estimated market cap

$59.00M (as of May 13, 2025)

Shares outstanding

500,000,000

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2023)

Poolbeg Pharma Plc leadership

• Jeremy Skillington — CEO
• Ian O'Connell — CFO

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with P